Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ventyx Biosciences

Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop

Ventyx Biosciences scrapped a psoriasis drug that didn't pass muster in Phase 2 testing on Tuesday, and VTYX stock crashed more than 80%.

Investors Business Daily

A $4 Billion Cash Payment Lifts This Small-Cap Biotech

Ventyx Biosciences jumped 20% after Takeda handed a competitor $4 billion in cash for rights to a drug candidate still in clinical trials.

The Street

Bristol Myers Squibb Shakes Up Key Biotech Battleground

The FDA approval of Sotyktu for psoriasis has both ignited and dampened prospects for smaller biotech stocks.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United Kingdom

100,100 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.